Table 2.
Between-group comparisons of clinical outcomes at 1-year follow-up.
| Variables | Oral Antipsychotic (n = 35) | LAI (n = 25) | χ2 or F | p-Value | Cramér’s V or η2 |
|---|---|---|---|---|---|
| Suicidal ideation, No. (%) | 13 (37.1%) | 2 (8.0%) | 6.61 | 0.010 | 0.29 |
| Relapses, No. (%) | 11 (31.4%) | 2 (8.0%) | 4.72 | 0.030 | 0.24 |
| Psychiatric hospitalizations, No. (%) | 9 (25.7%) | 1 (4.0%) | 4.95 | 0.026 | 0.24 |
| Drop out, No. (%) | 13 (37.1%) | 2 (8.0%) | 6.61 | 0.010 | 0.29 |
| BMI, mean ± SD | 29.93 ± 6.38 | 26.92 ± 3.07 | 5.89 | 0.019 | 0.09 |
| DAI-10, mean ± SD | 0.06 ± 4.72 | 3.52 ± 4.28 | 8.76 | 0.005 | 0.13 |
Significance set at p < 0.05 (two-tailed). Significant results are reported in bold. Abbreviations: BMI, body mass index; DAI-10, 10-item Drug Attitude Inventory; LAI(s), long-acting antipsychotic(s); n or No., number; SD, standard deviation.